Ladostigil

Ladostigil
Systematic (IUPAC) name
[(3R)-3-(prop-2-ynylamino)indan-5-yl]-N-propylcarbamate
Clinical data
Legal status
  • Uncontrolled
Routes of
administration
Oral
Identifiers
CAS Number 209349-27-4
ATC code None
PubChem CID 208907
ChemSpider 181005
UNII SW3H1USR4Q YesY
Synonyms [N-propargyl-(3R)-aminoindan-5yl]-N-propylcarbamate
Chemical data
Formula C16H20N2O2
Molar mass 272.34 g/mol

Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease.[1] It acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule.[2][3] In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis.[4] Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.[5][6]

See also

References

  1. Weinstock M, Bejar C, Wang RH, et al. (2000). "TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease". Journal of Neural Transmission. Supplementum (60): 157–69. PMID 11205137.
  2. Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). "Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 163–74. doi:10.1016/j.nurt.2008.10.030. PMID 19110207.
  3. Weinstock M, Luques L, Bejar C, Shoham S (2006). "Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression". Journal of Neural Transmission. Supplementum (70): 443–6. PMID 17017566.
  4. Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences 1122: 155–68. doi:10.1196/annals.1403.011. PMID 18077571.
  5. Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression". Psychopharmacology 160 (3): 318–24. doi:10.1007/s00213-001-0978-x. PMID 11889501.
  6. Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease". Progress in Neuro-psychopharmacology & Biological Psychiatry 27 (4): 555–61. doi:10.1016/S0278-5846(03)00053-8. PMID 12787840.


This article is issued from Wikipedia - version of the Tuesday, September 01, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.